BORA - UiB

Bergen Open Research Archive

The cost of multiple sclerosis in Norway

Bergen Open Research Archive

Show simple item record

dc.contributor.author Svendsen, Bjørn
dc.contributor.author Myhr, Kjell-Morten
dc.contributor.author Nyland, Harald Inge
dc.contributor.author Aarseth, Jan Harald
dc.date.accessioned 2011-03-11T10:03:17Z
dc.date.available 2011-03-11T10:03:17Z
dc.date.issued 2010-11-16
dc.identifier.citation The European Journal of Health Economics 1-11 en_US
dc.identifier.issn 1618-7598
dc.identifier.uri http://dx.doi.org/10.1007/s10198-010-0286-7
dc.identifier.uri http://hdl.handle.net/1956/4568
dc.description.abstract Health economic aspects have been increasingly important during introduction of new treatments for multiple sclerosis. As a partial response for Norway, a costof- illness study was carried out to estimate the yearly cost of the illness to society and relate costs and patients’ quality of life to illness severity. Estimated cost to society was Euro 439 million in 2002 exclusive of the cost of reduced quality of life. The cost per patient was close to Euro 65,000. Account taken of methodological differences, the results compare to results for Sweden, Norway’s closest neighboring country. The illness reduced patients’ quality of life with 0.26. More patients were early retired because of their MS in Norway than in any of nine other European countries comprised by a recent European study, illustrating a liberal practice in Norway. The Norwegian cost of unpaid assistance was almost identical to the Swedish cost that was the lowest found across the countries in the European study. When related to illness severity, the cost per patient increased, and the patients’ experienced quality of life decreased with increasing EDSS levels in line with what has been found for other countries. Cost-of-MS studies have been carried out for a number of countries. Together they contribute to our understanding of the economic consequences of multiple sclerosis and, if their results are related to illness severity, also provide valuable information for further economic analyses of treatment and medication. Our study adds to this. en_US
dc.language.iso eng en_US
dc.publisher Springer en
dc.rights Copyright The Author(s) 2010. This article is published with open access at Springerlink.com en_US
dc.rights.uri http://creativecommons.org/licenses/by-nc/2.5/ en_US
dc.subject Multiple sclerosis en
dc.subject Cost-of-illness en
dc.subject Quality of life en
dc.subject Relapse en
dc.subject EDSS en
dc.subject Norway en
dc.title The cost of multiple sclerosis in Norway en_US
dc.type Peer reviewed en_US
dc.type Journal article en_US
dc.subject.nsi VDP::Medical disciplines: 700 en_US
dc.rightsHolder The Author(s) 2010 en_US
dc.type.version publishedVersion en_US
bora.cristinID 922561


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Copyright The Author(s) 2010. This article is published with open access at Springerlink.com Except where otherwise noted, this item's license is described as Copyright The Author(s) 2010. This article is published with open access at Springerlink.com

Search BORA


Browse

My Account